Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2092612

Dyskinesia - Pipeline Review, H1 2012

Description:
Dyskinesia – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Dyskinesia - Pipeline Review, H1 2012', provides an overview of the Dyskinesia therapeutic pipeline. This report provides information on the therapeutic development for Dyskinesia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyskinesia. 'Dyskinesia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dyskinesia.
- A review of the Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dyskinesia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dyskinesia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Dyskinesia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Dyskinesia Therapeutic Products under Development, Key Players in Dyskinesia Therapeutics, Dyskinesia Pipeline Overview, Dyskinesia Pipeline, Dyskinesia Pipeline Assessment
 
Contents:


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dyskinesia Overview
Therapeutics Development
An Overview of Pipeline Products for Dyskinesia
Dyskinesia Therapeutics under Development by Companies
Dyskinesia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Dyskinesia Therapeutics – Products under Development by Companies
Dyskinesia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Dyskinesia Therapeutics Development
Merck & Co., Inc.
XenoPort, Inc.
Neurocrine Biosciences, Inc.
Cubist Pharmaceuticals, Inc.
Addex Pharmaceuticals
Medicure Inc.
NeuroSearch A/S
Neurim Pharmaceuticals (1991) Ltd.
Proximagen Neuroscience plc.
Santhera Pharmaceuticals Holding AG
EpiVax, Inc.
Adamas Pharmaceuticals, Inc.
QRxPharma Limited
Neuraltus Pharmaceuticals, Inc.
Dyskinesia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Dipraglurant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NBI-98854 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neu-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tardoxal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ordopidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naluzotan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botulinum Toxin Type A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fipamezole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Preladenant + Levodopa + Carbidopa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Botox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amlodipine + Botulinum toxin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Piracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T9001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAMORs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADS-5102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acamprosate Prodrug - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Prednisone + Gammaglobulin Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neu-240 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dyskinesia Therapeutics – Drug Profile Updates
Dyskinesia Therapeutics – Discontinued Products
Dyskinesia Therapeutics - Dormant Products
Dyskinesia – Product Development Milestones
Featured News & Press Releases
Jan 25, 2012: FDA Grants Fast Track Designation For Neurocrine's VMAT2 Inhibitor, NBI-98854
Jan 23, 2012: Medicure Provides Update On TEND-TD Phase II Clinical Trial
Jan 04, 2012: Merz Pharmaceuticals Receives J-Code For Xeomin From Centers For Medicare And Medicaid Services
Nov 17, 2011: Merz To Present XEOMIN Data At 72nd Annual Assembly Of American Academy Of Physical Medicine And Rehabilitation
Oct 21, 2011: Merz Research Shows Long-term Benefits For Patients With Dystonia
Sep 28, 2011: Adamas Pharmaceuticals Initiates Phase II/III Clinical Study Of ADS-5102 In Parkinson's Disease
Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854
Jun 23, 2011: Neurocrine Biosciences Announces Notice Of Allowance For Composition Of Matter Patent On VMAT2 Inhibitor
Apr 12, 2011: Merz's XEOMIN Data To Be Presented At 63rd Annual Meeting Of American Academy Of Neurology
Apr 05, 2011: Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial For VMAT2 Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Dyskinesia, H1 2012
Products under Development for Dyskinesia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Merck & Co., Inc., H1 2012
XenoPort, Inc., H1 2012
Neurocrine Biosciences, Inc., H1 2012
Cubist Pharmaceuticals, Inc., H1 2012
Addex Pharmaceuticals, H1 2012
Medicure Inc., H1 2012
NeuroSearch A/S, H1 2012
Neurim Pharmaceuticals (1991) Ltd., H1 2012
Proximagen Neuroscience plc., H1 2012
Santhera Pharmaceuticals Holding AG, H1 2012
EpiVax, Inc., H1 2012
Adamas Pharmaceuticals, Inc., H1 2012
QRxPharma Limited, H1 2012
Neuraltus Pharmaceuticals, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Dyskinesia Therapeutics – Drug Profile Updates
Dyskinesia Therapeutics – Discontinued Products
Dyskinesia Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Dyskinesia, H1 2012
Products under Development for Dyskinesia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2092612

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Wednesday, June 19, 2013
6:02:33 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Dyskinesia - Pipeline Review, H1 2012

Web Address

http://www.researchandmarkets.com/reports/2092612

Office Code

OC8DIQQMMNORWY

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EUR 382
Electronic (PDF) - Site License EUR 765
Electronic (PDF) - Enterprisewide EUR 1,147

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Wednesday, June 19, 2013
6:02:33 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)